Recruiting

Testing a new injectable treatment for sleep apnea in people with higher body weight

Plain-English translation of NCT06931028 on ClinicalTrials.gov ↗ · Source last updated June 2025 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing a medication called to see if it can help treat moderate-to-severe obstructive sleep apnea (a condition where breathing repeatedly stops and starts during sleep) in people who are overweight or obese. Half of the participants will receive the medication as a weekly injection under the skin, while the other half will receive a placebo (a dummy injection with no active drug). The study will track how well this treatment works and whether it's safe.

Obstructive sleep apnea is a serious condition that affects many people, especially those who are overweight, and current treatments don't work for everyone or aren't acceptable to all patients. Researchers want to see if this medication could offer a new treatment option for people who need better ways to manage their sleep apnea.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with moderate-to-severe obstructive sleep apnea confirmed by a sleep study
your body mass index (BMI) is 28 kg/m² or higher
you either use a PAP machine (continuous positive airway pressure) and are willing to continue using it, or you are unable or unwilling to use PAP therapy
you have not made significant weight loss changes (more than 5%) through diet and exercise alone in the past 12 weeks

You likely don't qualify if…

you have type 1 or type 2 diabetes
you have had previous sleep apnea surgery or major throat surgery that may still affect your breathing
you have significant facial or skull abnormalities that affect your breathing
you are currently using other active treatments for sleep apnea besides PAP therapy (such as dental devices)
you have other serious lung or neuromuscular diseases that could interfere with the study

What participation looks like

You would come for an initial screening visit (4 weeks), then receive once-weekly injections under your skin for 48 weeks—either the study medication or placebo. If you receive the active medication, the dose will gradually increase over the first 12 weeks, then stay at the highest dose for the remaining 36 weeks. After the 48-week treatment period ends, you'll have a 12-week follow-up period where researchers will check how you're doing. Throughout the study, you'll have sleep studies and visits to monitor how the treatment is working.

AI-generated summary from trial data · Jun 11, 2026 · Not medical advice

Trial locations(1 site)

China

Peking University Third Hospital, Beijing